Boundless Bio's Upcoming Appearance at Healthcare Conference

Boundless Bio's Participation in a Major Healthcare Conference

Boundless Bio, a pioneering clinical-stage oncology company, plans to participate in an important healthcare conference hosted by Piper Sandler. The company is focused on analyzing extrachromosomal DNA (ecDNA) biology, aiming to develop groundbreaking therapies for patients suffering from challenging oncogene amplified cancers.

Insights from the Conference Participation

Zachary Hornby, the President and CEO of Boundless Bio, is set to lead a fireside chat at Piper Sandler's 36th Annual Healthcare Conference. The session will take place on a Wednesday afternoon, a prime time for engagement with investors and collaborators. This platform will allow him to share insights and updates about the innovative approaches the company is adopting in oncology.

Live Webcast Details

For those interested in following this session, a live and archived webcast will be available. This provides an excellent opportunity for investors and interested parties to catch the session under the investment segment of Boundless Bio’s official website. These webcasts are a fantastic resource for staying updated with the latest developments in oncology research.

About Boundless Bio

Boundless Bio is on a mission to revolutionize cancer treatment. The company is specifically targeting extrachromosomal DNA (ecDNA), which significantly contributes to oncogene amplification in over 14% of cancer patients. With a focus on delivering effective therapies for these difficult cases, Boundless Bio presents a remarkable commitment toward addressing the unmet needs in oncology.

Innovative Therapies in Development

The company is advancing several therapies, including its first ecDNA-directed therapy, known as BBI-355. This oral inhibitor targets checkpoint kinase 1 (CHK1) and is currently undergoing Phase 1/2 clinical trials on patients with oncogene amplified tumors. Additionally, Boundless Bio is developing BBI-825, another oral therapy aimed at colorectal cancer patients featuring specific gene mutations. These innovative solutions showcase Boundless Bio's dedication to transforming treatment options available to oncologists and patients alike.

Groundbreaking Science and Future Goals

Boundless Bio continues to leverage its proprietary Spyglass platform, which is heavily invested in discovering new ecDNA-targeted therapies. An additional program, designated ecDTx 3, is also progressing through preclinical development stages. The ongoing research and innovation highlight Boundless Bio's position at the forefront of oncology therapeutics.

Contact Information

The company invites inquiries and provides a direct contact for interested parties. Reach out to Ben Flaum at Boundless Bio for further information about their projects and initiatives. Engaging with key representatives from the firm can lead to deeper insights into how they are impacting cancer research.

Frequently Asked Questions

What is Boundless Bio's main goal?

Boundless Bio aims to unlock new cancer therapies by targeting extrachromosomal DNA to help patients with oncogene amplified tumors.

Who is leading the discussion at the Piper Sandler Conference?

The discussion will be led by Zachary Hornby, the President and CEO of Boundless Bio.

How can I watch the conference session?

A webcast of the session will be available on Boundless Bio's website under their "Events & Presentations" section.

What therapies are currently in development by Boundless Bio?

Boundless Bio is developing BBI-355 and BBI-825, both targeting specific cancers and utilizing advanced ecDNA research.

How can I get in touch with Boundless Bio?

For inquiries, you can contact Ben Flaum at Boundless Bio or visit their website for more details.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.